Wegovy 0.25mg: What the Starting Dose Is Really For

Step 1, Why treatment begins at 0.25mg rather than a higher dose

Semaglutide slows gastric emptying and reduces appetite by acting on GLP-1 receptors. Both effects are real even at 0.25mg, but at this level they are mild enough that most people find the adjustment manageable. Starting low is a deliberate design choice in the licensed schedule: it reduces the risk of the nausea, vomiting and digestive discomfort that are the most common reasons people struggle in the early weeks of treatment.

Think of it as calibration rather than treatment. The 0.25mg pen is not intended to produce the weight-loss results that clinical trials measured, those were recorded at the 2.4mg maintenance dose. What it does is prepare your system so that when the dose increases, your body is far less likely to react sharply. A practical check worth doing in the first week: note roughly how your appetite feels at mealtimes and how you're sleeping. Some people notice subtle changes even at this dose; most don't see much on the scales, and that is entirely expected. You can read more about how the full Wegovy dose schedule is structured if you want the bigger picture before starting.

The licensed schedule sets 0.25mg for weeks one to four. Your prescriber decides the pace; it is never adjusted based on impatience alone.

Step 2, What to expect during your four weeks at 0.25mg

For many people, the 0.25mg phase is the roughest stretch, which sounds counterintuitive given it is the lowest dose. The reason is that any new exposure to semaglutide carries a GI adjustment period, and that period starts here. Nausea is the most commonly reported effect, typically most noticeable in the day or two after the injection, and it usually settles within the first fortnight.

Other effects that some people notice include constipation, loose stools, mild indigestion, or a feeling of fullness that arrives sooner than usual at meals. These are listed in the Wegovy prescribing information and discussed on the NHS semaglutide page. Staying well hydrated helps, and keeping meals smaller and lower in fat during this phase can ease the transition.

Injection technique matters too. The pen is designed for use in the abdomen, thigh, or upper arm, rotating the site each week reduces local irritation. If you are uncertain about what the pen looks like or how the injection volume is described, the volume details for the 0.25mg pen are worth reviewing before your first dose. Serious side effects at this stage are rare but include severe or persistent abdominal pain that radiates to the back, which should prompt urgent medical attention as a precaution against pancreatitis, a known but infrequent risk with GLP-1 medicines, flagged by the MHRA in January 2026.

Weight loss during these four weeks is usually minimal. Do not judge the treatment by this phase.

Step 3, Moving from 0.25mg to 0.5mg and what drives that decision

After four weeks, the standard next step is an increase to 0.5mg weekly. This is where the titration schedule gains momentum, and where many people begin to notice a more meaningful reduction in appetite. The move from 0.25mg to 0.5mg is a routine clinical step, not a significant threshold, but it does mark the shift from the adjustment phase to the early treatment phase.

Your prescriber reviews how the 0.25mg period went before confirming the increase. If side effects were significant and are still present, they may recommend staying at 0.25mg for a further four weeks. That is a legitimate clinical call, not a setback. Rushing the titration to reach the maintenance dose faster does not improve outcomes and increases the risk of persistent GI symptoms.

It also helps to understand how 0.25mg compares practically to the next step up. The differences between the two doses in terms of appetite suppression and tolerability are well characterised in the trial data. Most people tolerate the 0.5mg step well if the first four weeks have gone smoothly.

For context on what the full clinical picture looks like (including the NICE eligibility criteria and how private access through a regulated pharmacy differs from NHS routes) the Wegovy overview page covers the detail. And if cost is a consideration at this point in your thinking, our Wegovy cost page sets out what an honest private price actually includes.

Step 4, What the 0.25mg phase tells your clinical team

Every repeat order at nume goes through a fresh clinical review. How you got on during the 0.25mg phase (appetite changes, side-effect profile, any concerns) forms part of that picture. It is not box-ticking. A real prescriber reads your responses before anything is dispensed. That conversation also shapes the titration plan going forward, because the pace of dose increases is not one-size-fits-all.

If you are transferring from another provider and have already completed the 0.25mg phase, your clinical team will ask for evidence of your current dose before any supply. That protects you; jumping doses without that check creates unnecessary risk. Specific questions about your own situation are best put directly to our clinical team, the FAQs page covers many common ones, and our prescribers are available for aftercare seven days a week through the contact page.

The full dosage guidance for 0.25mg Wegovy goes into more practical detail for people who want the specifics before their first pen arrives. If you are ready to see whether Wegovy is clinically suitable for you, check your eligibility with our prescribers, the consultation is free, and a prescriber reviews every submission the same day.